|
Rhythm Pharmaceuticals, Inc. (RYTM) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Rhythm Pharmaceuticals, Inc. (RYTM) Bundle
Vereinfachen Sie die Rhythm Pharmaceuticals, Inc. (RYTM) Bewertung mit diesem anpassbaren DCF -Taschenrechner! Mit Real Rhythm Pharmaceuticals, Inc. (RYTM) -Fonds und einstellbaren Prognoseeingaben können Sie Szenarien testen und Rhythmus Pharmaceuticals, Inc. (RYTM) in Minuten fairen Wert aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 3.2 | 23.6 | 77.4 | 130.1 | 217.3 | 363.0 | 606.2 | 1,012.5 | 1,691.0 |
| Revenue Growth, % | 0 | 0 | 649.46 | 227.56 | 68.06 | 67.02 | 67.02 | 67.02 | 67.02 | 67.02 |
| EBITDA | -135.9 | -68.5 | -174.5 | -168.5 | -265.5 | -130.4 | -217.8 | -363.7 | -607.5 | -1,014.6 |
| EBITDA, % | 100 | -2170.39 | -738.28 | -217.58 | -204.04 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .7 | 1.2 | 1.4 | 1.8 | .0 | 63.0 | 105.2 | 175.7 | 293.5 | 490.1 |
| Depreciation, % | 100 | 36.72 | 5.94 | 2.27 | 0 | 28.98 | 28.98 | 28.98 | 28.98 | 28.98 |
| EBIT | -136.6 | -69.6 | -175.9 | -170.2 | -265.5 | -130.4 | -217.8 | -363.7 | -607.5 | -1,014.6 |
| EBIT, % | 100 | -2207.1 | -744.22 | -219.85 | -204.04 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 172.8 | 294.9 | 333.3 | 275.8 | 320.6 | 217.3 | 363.0 | 606.2 | 1,012.5 | 1,691.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1.0 | 6.2 | 14.9 | 18.5 | 83.6 | 139.6 | 233.1 | 389.3 | 650.2 |
| Account Receivables, % | 100 | 32.5 | 26.33 | 19.2 | 14.23 | 38.45 | 38.45 | 38.45 | 38.45 | 38.45 |
| Inventories | .0 | .1 | 2.9 | 8.6 | 18.7 | 61.5 | 102.6 | 171.4 | 286.3 | 478.2 |
| Inventories, % | 100 | 3.52 | 12.34 | 11.14 | 14.4 | 28.28 | 28.28 | 28.28 | 28.28 | 28.28 |
| Accounts Payable | 4.9 | 5.7 | 4.8 | 4.9 | 12.3 | 102.6 | 171.4 | 286.2 | 478.0 | 798.4 |
| Accounts Payable, % | 100 | 181.9 | 20.29 | 6.31 | 9.47 | 47.22 | 47.22 | 47.22 | 47.22 | 47.22 |
| Capital Expenditure | -.2 | -5.4 | -4.3 | .0 | .0 | -51.4 | -85.8 | -143.3 | -239.3 | -399.7 |
| Capital Expenditure, % | 100 | -172.29 | -18.11 | -0.06070155 | 0 | -23.63 | -23.63 | -23.63 | -23.63 | -23.63 |
| Tax Rate, % | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 |
| EBITAT | -133.2 | -68.0 | -177.8 | -170.7 | -269.9 | -129.2 | -215.7 | -360.3 | -601.7 | -1,005.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -127.9 | -72.6 | -189.6 | -183.3 | -276.2 | -135.0 | -224.7 | -375.3 | -626.8 | -1,046.9 |
| WACC, % | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 | 14.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,453.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,068 | |||||||||
| Terminal Value | -8,808 | |||||||||
| Present Terminal Value | -4,550 | |||||||||
| Enterprise Value | -6,004 | |||||||||
| Net Debt | -85 | |||||||||
| Equity Value | -5,918 | |||||||||
| Diluted Shares Outstanding, MM | 61 | |||||||||
| Equity Value Per Share | -97.03 |
What You Will Get
- Comprehensive RYTM Financials: Access to historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Dynamic calculations for intrinsic value and NPV.
- Scenario Testing: Evaluate various scenarios to assess Rhythm Pharmaceuticals' future outlook.
- User-Friendly Interface: Designed for professionals but easy for newcomers to navigate.
Key Features
- Comprehensive Historical Data: Rhythm Pharmaceuticals' financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Valuation: Instantly view Rhythm Pharmaceuticals' intrinsic value as calculations update live.
- Insightful Visualizations: Interactive dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Rhythm Pharmaceuticals, Inc. (RYTM).
- Step 2: Review the pre-filled financial data and forecasts specific to Rhythm Pharmaceuticals.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for informed investment decisions.
Why Choose This Calculator?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your analysis needs.
- Real-Time Feedback: Observe immediate updates to Rhythm Pharmaceuticals’ valuation as you tweak the inputs.
- Preloaded Data: Comes equipped with Rhythm Pharmaceuticals’ actual financial metrics for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Professionals: Understand the valuation of biopharmaceutical companies and apply it to real-world scenarios.
- Researchers: Utilize advanced models in studies related to drug development and market strategies.
- Investors: Evaluate your investment strategies and analyze the market performance of Rhythm Pharmaceuticals (RYTM).
- Financial Analysts: Enhance your analysis with a customizable DCF model specifically designed for biotech firms.
- Entrepreneurs: Learn from the valuation processes of established biopharmaceutical companies like Rhythm Pharmaceuticals (RYTM).
What the Template Contains
- Historical Data: Includes Rhythm Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Rhythm Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Rhythm Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.